New QP requirements 'in sync with real world', but EU drug industry concerns persist
This article was originally published in SRA
Pharmaceutical companies have largely welcomed the European Commission's revised draft guideline on qualified person (QP) requirements as the update aims to bring the document in line with the current globalized nature of the drug industry1,2. They are, however, worried about the practical implementation of some of the provisions in the proposed guideline, saying these could lead to unnecessary challenges "while feasible alternatives are at hand".
You may also be interested in...
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Thirty-eight guidance documents have been posted on the tracker since its last update.
New treatments for advanced endometrial cancer and hereditary angioedema are among six drugs that have just been recommended for EU-wide approval. Harmonized EU advice has also been issued in relation to an investigational antibody combination for treating COVID-19.
As part of its big data initiative, the European Medicines Agency is supporting projects that will help identify appropriate real-world data sources for regulatory decision making.